News Current page: 4

In January, SHS Partner André Zimmermann and SHS Investment Manager Hannes Kempter travelled to San Francisco for the J.P. Morgen Conference. For the first time in a long time, the weather was kind to the conference and was pleasantly sunny instead of the usual rainy weather. The atmosphere at the conference was also not dampened […]

In December 2023, the Federal Institute for Drugs and Medical Devices (BfArM) extended the reimbursement of Selfapy’s online course for generalised anxiety disorder to men. The BfArM thus confirms the results of additional real-world evidence (RWE), which shows that Selfapy’s product also significantly reduces anxiety symptoms and improves health-related quality of life in men with […]

At the end of 2023, the SHS portfolio company TRI received the SEF Growth High Potential Label from the Swiss Economic Forum. Founded in 2011, TRI began its journey with the goal of improving patient experience and outcomes with an innovative, digitalised approach to dental implantations. With TRI’s patented matrix implant technology – the world’s […]

Dr.Dropin opened its first clinic in Oslo, Norway, in 2017. The company now has over 25 clinics in Norway and Sweden, covering general medicine, dermatology, gynaecology, psychology and physiotherapy. The first clinic in the UK, located in London, Fulham, was opened at the end of 2023. The aim is to offer high-quality, personalised and easily […]

Mr Eisen, what exactly Blue Ocean Spine is focusing on and what milestones have you achieved in the development of your technology in recent years? Our aim is to improve the function and performance of existing products through the smart use of modern development and production technologies, while at the same time reducing manufacturing costs. […]

SHS presents itself in a new look since the beginning of this year. The last years at SHS have been characterised by great developments with a clear strategy for the future. And this also raised the question of how we want to communicate our identity, our development and our vision for the future to the […]

Patent applications in the field of medical technology and healthcare show a significant decline, now for the third year in a row The implementation of the new regulatory requirements (MDR/IVDR) has far-reaching effects on the German healthcare industry and is leading to a negative trend in new product developments The Medical Technology Index, developed by […]

After a four-year investment period, SHS Capital sells its shares in Betterguards Technology GmbH to Hochpfiffig GmbH Betterguards has developed a platform technology that protects human joints from ligament and tendon injuries Betterguards products are used in orthopaedic technology, occupational safety and also in the field of professional sports Tübingen / 14.12.2023 SHS Capital is […]

Once again this year, part of the SHS Capital team took part in the Tübingen St Nicholas Run. On 3 December, the St Nicholas Run, sponsored by itdesign GmbH among others, took place in Tübingen for the 48th time. Almost 2,750 participants successfully completed the half marathon. After the run, the participants enjoyed to lunch […]

Marie joined SHS at the beginning of September 2023. Marie began her studies with a Bachelor’s degree in European Economic Studies at the University of Bamberg, including a year abroad at Excelia Business School in La Rochelle, France. This was followed by a Master’s degree in Banking & International Finance at Toulouse Business School. Her […]

ESSERT Robotics was recently honored with the prestigious FANUC Innovation Award. The award was presented at the Robot Global Partner of the Year event in Tokyo, Japan. The ESSERT MicroFactory, an innovative and flexible production line, was recognized as a pioneering solution for Industry 4.0. The Award is one of the most prestigious awards and […]

We are pleased to announce that the Next Generation Sequencing technology used by our SHS Capital portfolio company PathoQuest for the safety of biologics has been highlighted in the ICHQ5A(R2) guideline adopted in November 2023. This global guideline is an important regulatory standard for the market. It states: “NGS is favoured as a replacement for […]